NCT03140176 - Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 15, 2017

Primary Completion Date

January 22, 2022

Study Completion Date

January 22, 2022

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG

Sunitinib

Sunitinib is an FDA approved targeted therapy for use as first line therapy for patients with metastatic renal cell carcinoma.

Trial Locations (8)

Kasr Al Aini, Cairo

National Cancer Institute, Cairo

Pierre Et Marie Curie Center, Algers

Kuwait Cancer Control Center, Kuwait City

CAC Annaba, Annaba

Hanene Djedi, Annaba

Demerdash Hospital, Cairo

Institut National D'Oncologie, Rabat